CARGO Therapeutics’ Post

🚀 Significant Progress in Precision Medicine for Long COVID & ME/CFS 🧬 PrecisionLife, under the leadership of CEO Dr. Steve Gardner, has recently achieved a major milestone in its ongoing efforts to combat long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The company has returned groundbreaking results from a 1,000-patient clinical trial conducted in partnership with the Metrodora Institute in Salt Lake City. This trial is crucial in validating PrecisionLife's innovative genotypic diagnostic test, which is set to revolutionize the approach to precision medicine. 🔍 Key Developments: PrecisionLife’s advanced combinatorial analytics have led to the identification of 73 novel genes linked to severe long COVID, many of which overlap with ME/CFS and other complex diseases. This discovery provides a deeper understanding of the genetic mechanisms behind these conditions. The company is paving the way for personalized treatment options, including drug repurposing strategies that target specific patient subgroups with mitochondrial, autoimmune, or neurotransmitter dysfunctions. 🌍 Impact and Innovation: These advancements hold the potential to significantly transform the diagnostic and treatment landscape for millions of patients who have long been underserved. By focusing on the underlying causes rather than just the symptoms, PrecisionLife is setting new standards in healthcare. 🔬 Oxford: The Innovation Hub Operating from its headquarters in Oxford, UK, Precision Life is leveraging the area’s strong academic and biotech ecosystem to drive innovation in computational biology and precision medicine. This strategic location supports the company’s global initiatives, including its partnership with the Metrodora Institute. Together, PrecisionLife and Metrodora Institute are rapidly advancing the development of life-changing diagnostics and treatments for patients in need. Stay tuned for more updates as these efforts continue to progress. #PrecisionMedicine #LongCOVID #MECFS #Genomics #HealthcareInnovation #Oxford

We are thrilled to announce our collaboration with Beckman Coulter Diagnostics to advance Alzheimer's disease testing. Kathleen Orland, Beckman Coulter SVP General Manager, Clinical Chemistry and Immunoassay, shared: “We selected ALZpath’s pTau217 antibody following rigorous evaluation due to its high performance in detecting amyloid pathology and ability to integrate into our advanced DxI 9000 platform to support broad-based testing. We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new fully automated, high throughput, blood-based Alzheimer's disease test for the millions of patients who suffer from dementia worldwide."   This partnership represents a significant step forward in our mission to democratize access to cutting-edge diagnostic tools and improve patient care. Together, we are pushing the boundaries of innovation to bring hope to millions of individuals and families affected by Alzheimer's disease.   📌 Read the full press release here: https://lnkd.in/gbvC4p4B   #AlzheimersDisease #Diagnostics #Innovation #Healthcare #Partnership #ALZpath #BeckmanCoulter #Biotech #MedicalResearch #pTau217 

Unlocking the Future of Medicine! 🌟 Dive into the groundbreaking world of targeted spatial profiling in multi-omics, where revolutionary therapeutic advances await. 🚀 Discover how this cutting-edge technology is reshaping healthcare as we know it: https://lnkd.in/esYzpV6P #MedicalInnovation #MultiOmics #TherapeuticAdvances #TargetedBioscience

DxA-funded RetiSpec recently announced a $10M Series A #funding round by investors like Eli Lilly and Company and Topcon Healthcare to advance the commercialization of its #AI-powered #EyeTest for the detection of #Alzheimers. #AI tools—like Retispec's—that can be used to predict #amyloid burden via #retinal scans are one of many #diagnostic tools in development that boost the #accessibility of early Alzheimer's detection. Learn more about the news here: https://bit.ly/4ggvRHU Medical Device Network

📢 Biological Dynamics Shutters Successor Firm to Advance Exosome Platform 🧬🔬 Big changes at Biological Dynamics! The company has made a strategic decision to shut down its successor firm to focus entirely on advancing its groundbreaking exosome platform. This move underscores their commitment to revolutionising diagnostics and precision medicine. 🌟 🔹 Strategic Focus: By concentrating resources on the exosome platform, Biological Dynamics aims to accelerate the development of innovative diagnostics that can transform patient care. 🔹 Innovative Technology: The exosome platform has the potential to provide early detection and monitoring of diseases, offering new hope for conditions like cancer and neurodegenerative diseases. 🔹 Company Statement: "We believe that focusing our efforts on the exosome platform will allow us to make the most significant impact in the diagnostics field. This technology holds immense promise for early disease detection and personalized medicine." What's Next? Biological Dynamics is poised to lead the way in exosome research and application, bringing new diagnostic solutions to market and improving outcomes for patients worldwide. #Biotech #HealthcareInnovation #ExosomeTechnology #Diagnostics #PrecisionMedicine #BiologicalDynamics #MedicalResearch #FutureOfHealthcare

Monday September 23rd Deals according to PitchBook Starting the week out strong in the investment landscape. Some biotechs, a huge raise by Vicebio, some health services... Congrats to all :) VerImmune - Raise of $4.5M - Developer of biotechnology immuno-medicines designed to provide cancer therapy known as anti-tumor immune redirection. - Joshua Weiyuan Wang Ph.D. Vicebio - Series B raise of $100M - Developer of innovative vaccines designed to target respiratory viral infectious diseases. Emmanuel Hanon Surgicure Technologies, Inc. - Seed raise of $2M - Operator of a medical device company intended to innovate airway management for civilian and military use. - Irena King Soihtu DTx - Seed raise of $3.33M - Operator of a depression treatment firm intended to develop an innovative digital therapy in the form of a video game. Jukka Laakso Qure.ai - Series D raise of $.77M - Developer of an automated interpretation device designed to make healthcare affordable and accessible. Prashant Warier MedBeat - Angel raise of $.15M - Developer of ECG modules and applications designed to detect arrhythmia outside hospitals to prevent stroke and sudden cardiac death. Erik Rask exakt health - Raise of $2.2M - Developer of a healthcare platform designed to provide access to professional physiotherapy. Philip Billaudelle #medicaldevices #lifesciences #biopharma #biotechnology #medtech #healthtech #AI #robotics #venturecapital #vc #deals #money #dailyrecap #ceo #coo #sales #marketing #management #operations #regulatory #quality #clinical #genomics #geneediting #moleculardiagnostics #hospital #healthcare #remotepatientmonitoring #therapeutics #woundcare #oncology #orthopaedics #neurology #cardiology #CRO #CDMO #digital #ocular #radiology #diagnostics 

𝑬𝒎𝒆𝒓𝒈𝒊𝒏𝒈 𝑻𝒓𝒆𝒏𝒅𝒔 𝒂𝒏𝒅 𝑮𝒓𝒐𝒘𝒕𝒉 𝑷𝒓𝒐𝒔𝒑𝒆𝒄𝒕𝒔 𝒊𝒏 𝒕𝒉𝒆 𝑮𝒍𝒐𝒃𝒂𝒍 𝑪𝒂𝒓𝒅𝒊𝒂𝒄 𝑩𝒊𝒐𝒎𝒂𝒓𝒌𝒆𝒓𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 𝑺𝒆𝒄𝒖𝒓𝒆 𝒂 𝑭𝑹𝑬𝑬 𝑺𝒂𝒎𝒑𝒍𝒆: https://lnkd.in/gQPEgh4h The 𝑪𝒂𝒓𝒅𝒊𝒂𝒄 𝑩𝒊𝒐𝒎𝒂𝒓𝒌𝒆𝒓𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 is on a rapid growth trajectory, driven by increasing incidences of cardiovascular diseases and advancements in diagnostic technologies. As we continue to navigate through a healthcare landscape increasingly focused on precision medicine, the role of cardiac biomarkers in early detection and personalized treatment plans cannot be overstated. 𝑴𝒂𝒓𝒌𝒆𝒕 𝑰𝒏𝒔𝒊𝒈𝒉𝒕𝒔: The global cardiac biomarkers market is expected to grow significantly in the coming years. Key drivers include the rising prevalence of cardiovascular diseases, increasing awareness about early diagnosis, and technological advancements in biomarker research. North America and Europe are leading regions due to advanced healthcare infrastructure and high investment in R&D. 𝑻𝒆𝒄𝒉𝒏𝒐𝒍𝒐𝒈𝒊𝒄𝒂𝒍 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕𝒔: Innovations in biomarker discovery are enhancing the sensitivity and specificity of diagnostic tests. Integration of AI and machine learning is revolutionizing data analysis, leading to more accurate and timely diagnoses. 𝑲𝒆𝒚 𝑷𝒍𝒂𝒚𝒆𝒓𝒔: Some of the major market players include Roche Diagnostics UK & Ireland, Siemens, Abbott, Alere Inc., Bio-Rad Laboratories, BD, bioMérieux, Beckman Coulter Diagnostics, Randox, and Thermo Fisher Scientific among others. 𝑨𝒄𝒄𝒆𝒔𝒔 𝑭𝒖𝒍𝒍 𝑹𝒆𝒑𝒐𝒓𝒕: https://lnkd.in/gGR2H8Tq 𝑭𝒖𝒕𝒖𝒓𝒆 𝑶𝒖𝒕𝒍𝒐𝒐𝒌: With continuous R&D, new biomarkers are being identified, offering potential for better management of cardiovascular diseases. Collaboration between biotech companies, healthcare providers, and research institutions is crucial for driving innovation and accessibility. 𝑰𝒎𝒑𝒂𝒄𝒕 𝒐𝒏 𝑯𝒆𝒂𝒍𝒕𝒉𝒄𝒂𝒓𝒆: Early detection through biomarkers can significantly reduce mortality rates and improve patient outcomes. Personalized medicine, guided by biomarker insights, promises more effective and targeted treatment plans. Stay tuned as we keep an eye on this dynamic market, poised to make significant strides in enhancing cardiovascular health worldwide. #cardiacbiomarkers #healthcareinnovation #medicalresearch #cardiovascularhealth #biotech #precisionmedicine #healthcaretransformation #markettrends

In the search for advanced #diagnostic tools and therapies, the #Neomer library emerges as a game-changer in #molecularbiology. It enables researchers to use identical sequences across diverse targets, offering a unique window into aptamer structures' characterization and manipulation. This not only deepens our understanding but also paves the way for strategic #aptamer design, mirroring nature's evolutionary tactics. With this approach, we're not just following in nature's footsteps—we're anticipating the future of #healthcare innovations. By forming collaborations that leverage these insights, we stand on the brink of transforming diagnostic applications and #therapeutic strategies. Dive into this revolutionary journey with us as we harness the full potential of #aptamers for a healthier tomorrow! https://lnkd.in/gMx2TDvj

Proud of the Decode Health team, led by Chase Spurlock, for delivering consistent growth and innovation in precision medicine. We were doing #AI in #healthcare and #lifesciences before it was cool. Our partners in the #biomarker discovery world, #pharma and #diagnostics, need our fast, accurate technology to deliver speed to value for their customers. LaunchTN #LifeScienceTennessee #RNA #genomics #clinicaldecisionsupport #autoimmunedisease

Our ALZpath pTau217 antibody was recently featured in Medical Device Network. Genova Diagnostics, in partnership with Neurocode Labs, Inc., has launched a new Alzheimer’s Assessment blood test that utilizes the pTau217 biomarker for early detection of Alzheimer’s disease—before the onset of clinical symptoms.   This innovative test represents a significant step forward in making Alzheimer’s diagnostics more accessible, allowing for earlier intervention and improved management of the disease. We're proud to be a part of this crucial development, contributing our proprietary #pTau217 antibody to help revolutionize how Alzheimer's is detected and managed.   The growing acceptance of Tau biomarkers in blood for Alzheimer’s screening is a testament to the dedication and innovation within the field, and we're honored to see our technology playing a pivotal role in this evolution.   Stay tuned for more updates as we continue our mission to democratize access to life-changing diagnostics and improve patient care globally. 📌Interested in learning more? Read the full article here: https://lnkd.in/dVyWxw6y 📌Want to learn more about ALZpath? Visit our website to discover how we’re advancing Alzheimer’s research and enhancing patient care: www.alzpath.bio   #ALZpath #AlzheimersDisease #pTau217 #EarlyDetection #Neurocode #BiotechInnovation